Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 18Terminated 3Active not recruiting 2

Sponsor Class

OTHER 24INDUSTRY 4NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1

Interventions

Radiotherapy 41Cisplatin 36Fluorouracil 17Paclitaxel 15Docetaxel 14Cyclophosphamide 14Carboplatin 14Filgrastim 13Doxorubicin 13Gemcitabine 11Etoposide 11Capecitabine 10Surgical Procedures, Operative 9Methotrexate 9Leucovorin 9Chemotherapy, Adjuvant 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Oxaliplatin 8Dexamethasone 7Bevacizumab 7Topotecan 6Radiotherapy, Conformal 6Prednisone 6Fenretinide 6Cetuximab 6Neoadjuvant Therapy 5Mitomycin 5Irinotecan 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × NETWORK × Epirubicin × Clear all
NCT00625898 2020-09-10

BETH

NSABP Foundation Inc

Phase 3 Terminated
3,509 enrolled
Breast

Breast Neoplasms

NCT00066807 2016-10-28

PERCHE

ETOP IBCSG Partners Foundation

Phase 3 Terminated
29 enrolled 6 charts
Breast

Breast Neoplasms

NCT01123473 2016-10-12

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
29 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡